
Vaxxinity, Inc. (NASDAQ:VAXX) announced that UB-311 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
UB-311 has been well tolerated in mild-to-moderate AD patients over three years of repeat dosing, with a safety profile comparable to placebo in the Phase 2a clinical trials